Body Protection Compound (BPC) Variants
Overview
BPC variants are synthetic peptide sequences related to a pentadecapeptide derived from human gastric juice, commonly designated BPC-157. These peptides are proposed to exhibit gastroprotective, angiogenic, and tissue repair properties through mechanisms that may involve nitric oxide pathways, growth factor modulation, and VEGF receptor interactions. The exact structure-activity relationships and receptor targets remain incompletely defined.
Key Research Findings
Preclinical rodent studies have reported accelerated healing of tendons, ligaments, and gastrointestinal lesions, along with protective effects in models of toxin-induced organ injury. Published research has primarily originated from a single research group, and independent replication is limited. No controlled clinical trials in humans have been published in peer-reviewed journals, and the compound lacks regulatory approval in any jurisdiction.
Subcutaneous injection, Oral
Research Phase
Interested in Body Protection Compound (BPC) Variants?
Find a verified provider experienced with Body Protection Compound (BPC) Variants protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Body Protection Compound (BPC) Variants ProviderRelated Peptides
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis and the expression of growth factors including VEGF, EGF, and NO-mediated pathways. It has demonstrated cytoprotective and wound-healing properties across multiple tissue types in preclinical models, including tendon, muscle, ligament, and gastrointestinal mucosa.
TB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue repair. It promotes wound healing by upregulating cell-building proteins such as actin and laminin, facilitating cell migration to sites of injury. TB-500 also has anti-inflammatory properties mediated through NF-kB pathway modulation.
GHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. GHK-Cu activates tissue remodeling by stimulating collagen synthesis, glycosaminoglycan production, and angiogenesis while suppressing fibrinogen synthesis. It modulates the activity of matrix metalloproteinases and influences over 4,000 genes related to tissue repair.
DSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers. It also exhibits stress-protective, analgesic, and neuromodulatory properties.